MMJ International Holdings Announces US Patent Filing for Multiple Sclerosis Cannabinoid Treatment

MMJ BioScience Proceeding with FDA Multiple Sclerosis Clinical Trial of Medicinal Cannabis 2018
November 13, 2017
MMJ BioScience Files Pre Investigational New Drug (IND) Application With FDA For Pharmaceutical Cannabidiol (CBD) derived medicine.
December 12, 2017

MMJ International Holdings Announces US Patent Filing for Multiple Sclerosis Cannabinoid Treatment

MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, today announced that it has filed a patent invention with the United States Patent and Trademark Office that relates to pharmaceutical compounds and methods for treating and/or preventing symptoms associated with cannabinoid responsive diseases and disorders, such as multiple sclerosis (MS), and to pharmaceutical compounds and methods for treating and/or preventing symptoms associated with said diseases and disorders.

MMJ BioScience’s intellectual property portfolio includes multiple patent families with issued and/or pending claims directed to plants, plant extracts, patient monitoring technology, pharmaceutical formulations, drug delivery methods and the therapeutic uses of cannabinoids, as well as plant variety rights, know-how and trade secrets.The MMJ BioScience filing of these patents protects the delivery of its MMJ BioScience® product formulation in its upcoming multiple sclerosis FDA study.

Dr. Bianca Weinstock-Guttman is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium will execute the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients. MMJ BioScience’s will be providing new evidence regarding clinical outcomes leading to commercial success in the scientific process of MMJ BioScience’s first pharmaceutical cannabidiol (CBD) derived medicine.

“Our initiation of the Phase 2 clinical trial programs and the eventual FDA Fast Track Designation for Progressive Multiple Sclerosis signify important steps forward in MMJ BioScience’s ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients,” stated Timothy Moynahan the companies chairman.

“We believe that this matrix of intellectual property provides MMJ Bioscience with a unique market position to benefit from the rich opportunities within the field of cannabinoid therapeutics.” further stated Timothy Moynahan.

According to the FDA, Fast Track Designation it is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need In the U.S. The FDA Orphan Drug Designation is granted to medicines and biologics that are defined as those intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S.

MMJ BioScience’s discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, contract processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.

Comments are closed.